Phathom Pharmaceuticals
PHAT
117 hedge funds and large institutions have $504M invested in Phathom Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 50 increasing their positions, 22 reducing their positions, and 17 closing their positions.
439% more call options, than puts
Call options by funds: $415K | Put options by funds: $77K
127% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 22
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
47% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 17
17.7% more ownership
Funds ownership: 77.04% → 94.74% (+18%)
11% more capital invested
Capital invested by funds: $453M → $504M (+$51.7M)
6% more funds holding
Funds holding: 110 → 117 (+7)
Top Buyers
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$5.89M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$4.72M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$3.07M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.7M |
| 5 |
BlackRock
New York
|
+$2.08M |
Top Sellers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.32M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$4.22M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$2.39M |
| 4 |
ACM
Altium Capital Management
New York
|
-$2.28M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.28M |
PHAT Hedge Fund Activity: Q4 2023 in Review
117 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q4 2023, worth a combined $504M — up 11% from $453M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PHAT positions and 17 closed out — a net gain of 8 holders — while 50 added to existing stakes and 22 trimmed.
The largest buyer was NEA Management Company, adding an estimated $5.89M. The largest seller was EcoR1 Capital, cutting an estimated $4.32M.
- 117 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q4 2023, up from 110 in Q3 2023.
- Funds reported $504M of Phathom Pharmaceuticals stock for Q4 2023, up 11% quarter-over-quarter.
- 25 funds opened new Phathom Pharmaceuticals positions in Q4 2023 and 17 closed out, a net change of +8 holders.
- The largest Phathom Pharmaceuticals buyer in Q4 2023 was NEA Management Company, an estimated $5.89M added.
- The largest Phathom Pharmaceuticals seller in Q4 2023 was EcoR1 Capital, an estimated $4.32M sold.
Based on aggregated 13F filings for Q4 2023.